Halberd Corp. (OTC: HALB) shares saw substantial gains during Wednesday’s trading session, closing with a remarkable 34.50% increase, marking a surge that was 4.5 times higher than the average 60-day volume. On December 13, 2023, the company garnered attention as it announced a comprehensive agreement with CrodenHealth.com. This collaboration encompasses various aspects, including the production, marketing, sales, and global distribution of Halberd’s patented low-dose naltrexone combo offering. The terms of the agreement also granted CrodenHealth.com the right of first refusal for future products emerging from Halberd’s development pipeline.
The press release also disclosed that Peter Croden, Chairman of the Board at CrodenHealth, brings substantial expertise to the table with over three decades of experience in the pharmaceutical industry. Collectively, the experience of Peter Croden, his son Brad Croden, and nephew Todd Croden spans more than five decades in the pharmaceutical sector. In collaboration with Halberd, CrodenHealth will play a role in joint venture development, funding, and drug certification initiatives.
CrodenHealth Brand’s CEO, Croden, shared insights on the deal yesterday, expressing the company’s excitement about capitalizing on both the present and future intellectual property of Halberd. This collaboration is poised to create new, profitable revenue streams for CrodenHealth. He concluded by emphasizing that this agreement marks the beginning of a promising, long-term partnership.
William A. Hartman, the CEO, President, and Chairman of Halberd, acknowledged CrodenHealth’s impressive track record in similar collaborations with major pharmaceutical companies and highlighted its extensive network. The partnership is expected to be mutually beneficial, signaling a promising start to a lasting relationship. The stock of Halberd Corp. (OTC: HALB) is presently trading at $0.0045 and seems to be on an upward trend, making it a stock worth monitoring, given its 52-week high of $0.0196.
Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors with a safe harbor with regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, and assumptions about future events or performance are not statements of historical fact and may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or due to the speculative nature of the companies profiled. TheStreetReports (TSR) is responsible for the production and distribution of this content.”TSR” is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. “TSR” authors, contributors, or its agents, may be compensated for preparing research, video graphics, podcasts and editorial content. “TSR” has not been compensated to produce content related to “Any Companies” appearing herein. As part of that content, readers, subscribers, and everyone viewing this content are expected to read the full disclaimer in our website.